関連レポート

パーキンソン病治療薬の世界市場：2031年予測

出版元：Transparency Market Research  出版元について

発行年：2024年1月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 172ページになります。

商品コード：TMR203

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

アルツハイマー型認知症治療薬の世界市場規模は2022年で63億ドル、2031年に93億ドル、市場の平均年成長率は4.6%にて増加する見込みです。

当レポートでは、アルツハイマー型認知症治療薬の市場予測-2031年、各種セグメント別市場分析(ドラッグクラス別、流通チャネル別、国地域別、等)、市場ダイナミクス、パイプライン分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。


【レポート構成概要】
■アルツハイマー型認知症治療薬の世界市場予測2017-2031年
・市場規模(US$)

■ドラッグクラス別、市場-2031年
・コリン作動性/コリンエステラーゼ（ChE）阻害薬
・メマンチン
・併用薬（メマンチンとドネペジル）
・その他
※(市場規模US$)

■流通チャネル別、市場-2031年
・院内薬局
・小売り
・オンライン販売
※(市場規模US$)

■主要国地域別市場-2031年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
・市場ダイナミクス
・パイプライン分析
・市場シェア分析
・競合状況

■アルツハイマー型認知症治療薬の主要企業プロフィール動向
Merz Pharma
Novartis AG
AbbVie Inc.
Pfizer, Inc.
第一三共株式会社
小野薬品工業株式会社
Johnson & Johnson Services, Inc.
エーザイ株式会社
H. Lundbeck A/S
F. Hoffmann-La Roche Ltd.


（全172頁）

Table of Contents (英文詳細目次）

1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Dementia Associated with Alzheimer’s Disease Market

4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecasts, 2017-2031

5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
5.3. COVID-19 Pandemic Impact on Industry

6. Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Cholinergic/Cholinesterase (ChE) Inhibitors
6.3.2. Memantine
6.3.3. Combined Drugs (Memantine & Donepezil)
6.3.4. Others
6.4. Market Attractiveness, by Drug Class

7. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Distribution Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Retail
7.3.3. Online Sales
7.4. Market Attractiveness, by Distribution Channel

8. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region

9. North America Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Class, 2017–2031
9.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
9.2.2. Memantine
9.2.3. Combined Drugs (Memantine & Donepezil)
9.2.4. Others
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail
9.3.3. Online Sales
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country

10. Europe Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2031
10.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
10.2.2. Memantine
10.2.3. Combined Drugs (Memantine & Donepezil)
10.2.4. Others
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail
10.3.3. Online Sales
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region

11. Asia Pacific Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2031
11.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
11.2.2. Memantine
11.2.3. Combined Drugs (Memantine & Donepezil)
11.2.4. Others
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Retail
11.3.3. Online Sales
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region

12. Latin America Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
12.2.2. Memantine
12.2.3. Combined Drugs (Memantine & Donepezil)
12.2.4. Others
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Retail
12.3.3. Online Sales
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region

13. Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
13.2.2. Memantine
13.2.3. Combined Drugs (Memantine & Donepezil)
13.2.4. Others
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Retail
13.3.3. Online Sales
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Merz Pharma
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Novartis AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. AbbVie Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Pfizer, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Daiichi Sankyo Company, Limited.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Ono Pharmaceutical Co., Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Johnson & Johnson Services, Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Eisai Co., Ltd.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. H. Lundbeck A/S
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. F. Hoffmann-La Roche Ltd.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview

List of Tables

Table 1: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 2: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 3: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 4: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 5: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 6: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 7: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 8: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 9: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031

Table 10: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 11: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 12: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 15: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031

Table 16: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 18: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031

List of Figures

Figure 1: Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

Figure 2: Global Dementia Associated with Alzheimer’s Disease Market Value Share, by Drug Class, 2022

Figure 3: Global Dementia Associated with Alzheimer’s Disease Market Value Share, by Distribution Channel, 2022

Figure 4: Global Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 5: Global Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 6: Global Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 7: Global Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 8: Global Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Region, 2022 and 2031

Figure 9: Global Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Region, 2023–2031

Figure 10: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

Figure 11: North America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country, 2022 and 2031

Figure 12: North America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country, 2023–2031

Figure 13: North America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 14: North America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 15: North America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 16: North America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 17: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

Figure 18: Europe Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 19: Europe Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 20: Europe Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 21: Europe Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 22: Europe Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 23: Europe Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 24: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

Figure 25: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 26: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 27: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 28: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 29: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 30: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 31: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, 2017–2031

Figure 32: Latin America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 33: Latin America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 34: Latin America Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 35: Latin America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 36: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 37: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 38: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 39: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 40: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 41: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis, by Distribution Channel 2023–2031

Figure 42: Global Dementia Associated with Alzheimer’s Disease Market Share Analysis, by Company (2022)

△ 一番上に戻る